Active-ingredient Dossier

Pegfilgrastim

Active-ingredient Dossier for Pegfilgrastim (granulocyte colony stimulating factor). Australian brands, products, PBS listings, PBAC outcomes — compiled…

Brand: ZIEXTENZO
Brand: FILPEGLA
Brand: PELGRAZ
Brand: FULPHILA
Brand: NEUTROPEG
Therapeutic area: Oncology

What is

Pegfilgrastim Pegfilgrastim is a granulocyte colony stimulating factor.

Australian brands containing

Pegfilgrastim — ZIEXTENZO — PELGRAZ — FULPHILA — FILPEGLA — NEUTROPEG

Therapeutic areas

Pegfilgrastim is registered in oncology, with five brands containing the ingredient on the ARTG.

Sponsor landscape

Four sponsors market pegfilgrastim in Australia: Accord Healthcare, Cipla, Maxx Pharma, and Sandoz.

PBS and regulatory activity

One brand containing pegfilgrastim has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2019–20 financial year, government expenditure on pegfilgrastim totalled approximately $82 million across 69,801 prescriptions. The latest PBAC outcome for pegfilgrastim was recorded on 1 March 2020, with four brands having PBAC outcomes on record. The latest AusPAR was dated 1 August 2022, with two brands having AusPARs on record.